Sofra™ breakthrough science published in major medical journal

Highlights

- ***Nature Immunology* publication highlights importance of discovery underpinning Sofra platform**
- **New understanding of how immune system works**
- **Independent US expert endorses research breakthrough**

Sydney, 11 February 2026: Clinical-stage biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce the publication of a scientific paper detailing the breakthrough science underlying the Sofra™ platform in a major medical journal.

Nature Immunology is the top-ranking peer-reviewed journal for primary research in immunology, known for publishing highly-cited articles that advance our understanding of the immune system.

The paper is titled '*2'-O-Methyl-guanosine RNA fragments antagonize TLR7 and TLR8 to limit autoimmunity*' and its lead author is Professor Michael Gantier of Hudson Institute of Medical Research, who is Noxopharm's exclusive strategic partner in the development of the technology.

Three Noxopharm employees are also authors of the paper, which additionally includes contributions from the University of Tokyo, Australian National University, Western Sydney University, Integrated DNA Technologies Inc, the Francis Crick Institute, CSIRO, Monash University and Sydney University, among others.

The paper describes the groundbreaking discovery of a novel anti-inflammatory mechanism, which is crucial for safeguarding against autoimmune disorders. These insights have enabled the subsequent development of innovative therapeutics, with Noxopharm's SOF-SKN™ emerging as a pioneering solution for autoimmune skin conditions.

The paper itself can be accessed online here, while a shorter layman's explanation of the science is on the Noxopharm website here.

Professor Arthur Krieg from UMass Chan Medical School RNA Therapeutics Institute in the US is one of the world's foremost experts on oligonucleotides and the immune system, having published more than 250 scientific papers and been an inventor on over 50 patents. Recognising the breakthrough research presented in the paper, he said: "This tour de force from Professor Gantier and his team has transformed our understanding of how immune sensors for viral infections are normally blocked to prevent autoimmunity. Their elegant and fundamental discovery provides a pathway to support the development of new medicines."

Professor Michael Gantier of Hudson Institute said: "After working in autoimmunity for over two decades, the publication of this landmark paper is the result of more than six years of research from my team working in close collaboration with Noxopharm. The scientific

breakthrough we report revolutionises our understanding of how inflammation is triggered, how it can lead to autoimmune diseases, and the therapeutic opportunities it represents.

“I would like to thank everyone involved for their dedication and commitment to securing this successful outcome, and look forward to continuing to work with the Noxopharm team as we further develop the technology to treat patients.”

Noxopharm CEO Dr Gisela Mautner said: “Publication of this collaborative work in a peer-reviewed journal as prestigious as *Nature Immunology* is clear evidence that we are building our Sofra platform on very solid foundations. The sophistication of the research has opened the door to the development of promising new drugs for diseases that have a strong inflammatory component like lupus, psoriasis, diabetes and rheumatoid arthritis.

“Following the publication of the paper, we now expect even greater interest in our work as the word spreads about our technology and its potential.”

-ENDS-

About the Sofra technology platform

Developed from a breakthrough discovery in the immune system, Sofra comprises a novel class of drugs targeting inflammatory and autoimmune diseases, as well as RNA therapeutics and vaccines.

Sofra technology has potential applications in a wide range of diseases related to the immune system such as rheumatoid arthritis, lupus and diabetes, as well as other diseases like cancer.

The global autoimmune disease therapeutics market was worth US$163.2 billion in 2024 and is expected to reach US$219.6 billion by 2035, while the worldwide immuno-oncology market was US$43 billion in 2023 and is projected to hit US$284 billion by 2033.

The proprietary platform is based on short nucleic acid sequences, the building blocks of DNA or RNA, known as oligonucleotides. These act on specific immune sensors to regulate inflammation at its source, reducing or stimulating it to control the disease.

Further information and animations: SOF-SKN / SOF-VAC

About Noxopharm

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).

To learn more, please visit: noxopharm.com

About Hudson Institute of Medical Research

A global bioscience medical research leader, Hudson Institute's sole focus is on powering breakthrough scientific discoveries into improved health care that will transform lives. We strive to improve human health through ground-breaking, collaborative medical research discoveries and their translation to real world impact. Hudson Institute scientists research five areas of medical need:

- Inflammation
- Reproductive health and pregnancy
- Infant and child health
- Cancer
- Hormones and health

To learn more, please visit: www.hudson.org.au

Investor, Corporate & Media enquiries:
Julian Elliott
M: 0425 840 071
E: julian.elliott@noxopharm.com

Company Secretary:
David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Hudson Institute Media enquiries:
Rob Clancy
Communications & Media Manager
M: + 61 408 579 313
E: rob.clancy@hudson.org.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.